In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Adicet Bio (ACET – Research Report), with a price target of $30.00. The company’s shares closed last Thursday at $12.30.
According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of -12.0% and a 31.8% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $32.00 average price target, a 158.1% upside from current levels. In a report released today, JonesTrading also maintained a Buy rating on the stock with a $33.00 price target.
The company has a one-year high of $18.49 and a one-year low of $6.25. Currently, Adicet Bio has an average volume of 1.19M.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACET in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
Read More on ACET: